Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 8th - 14th, 2022.
Alerts this week cover the FDA’s accelerated approval of fam-trastuzumad deruxtecan-nxki for HER2-mutant NSCLC. In addition to the FDA’s approval of capmatinib for metastatic NSCLC.
He also reminds everybody that ASCO Plenary Series 2022 is coming up this week where he will be reporting in real-time along with the OncoAlert GU faculty.
You can watch Dr Morgan's previous roundup here
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer